Charcot neuro-osteoarthropathy (CN), often called the Charcot foot, is one of the most serious and frequently misdiagnosed complications of diabetes. It is an inflammatory condition affecting the bones, joints, and soft tissues of the foot and ankle in people who have lost protective sensation from peripheral neuropathy. When it goes unrecognized, a foot that begins as merely warm and swollen can progress within weeks to profound bony collapse, ulceration, infection, and ultimately amputation. Because the window for effective, limb-preserving treatment is narrow, understanding how Charcot foot is recognized and managed matters for patients, caregivers, and clinicians alike.
What Happens in the Charcot Foot
Charcot neuroarthropathy develops in a foot that has been rendered insensate by diabetic peripheral neuropathy. The precise trigger remains incompletely understood, but current evidence points to an uncontrolled local inflammatory response as the central mechanism. Reviews of the pathophysiology describe how pro-inflammatory signaling activates the RANK/RANK-L/osteoprotegerin pathway, driving the differentiation of monocytes into bone-resorbing osteoclasts (Pitocco et al., Current Diabetes Reviews, 2019; Cellier, EFORT Open Reviews, 2025). The result is a cycle of increased bone turnover, weakening, fracture, and joint dislocation. Because the foot cannot feel pain, the patient keeps walking on it, and repetitive mechanical trauma accelerates the destruction. Autonomic neuropathy, which increases blood flow to bone, and advanced glycation end products, which alter tissue mechanics, are believed to compound the process.
Why Early Diagnosis Is So Difficult
The earliest stage of Charcot foot is deceptively benign in appearance. The classic presentation is a unilateral foot that is red, warm, and swollen, often with a skin temperature several degrees higher than the opposite limb, but with little or no pain despite dramatic underlying bone changes. This picture is easily mistaken for cellulitis, gout, deep vein thrombosis, or a simple sprain, which is why delays in diagnosis are common and consequential (Bansod et al., Cureus, 2023).
The 2023 guidelines from the International Working Group on the Diabetic Foot (IWGDF) emphasize that any patient with diabetes, neuropathy, and a warm, swollen foot should be presumed to have active Charcot neuroarthropathy until proven otherwise (Wukich et al., Diabetes/Metabolism Research and Reviews, 2023). Plain radiographs may appear normal in the very earliest (“stage 0”) phase, before fractures are visible. For this reason, magnetic resonance imaging is the preferred tool when suspicion is high, because it can detect the bone marrow edema and subtle stress injuries that precede visible collapse. MRI also helps address one of the most difficult distinctions in diabetic foot care: separating Charcot changes from osteomyelitis, an infection of bone that requires an entirely different treatment approach.
Offloading and Immobilization: The Foundation of Treatment
Once active Charcot foot is suspected, treatment should begin immediately rather than waiting for imaging confirmation. The cornerstone of management is complete offloading and immobilization of the affected limb. The IWGDF and multiple reviews identify the total contact cast (TCC), or an equivalent rigid, non-removable knee-high device, as the treatment of choice, maintained until the acute inflammation resolves and the affected bones consolidate (Wukich et al., 2023; Kavitha et al., Advances in Experimental Medicine and Biology, 2021). This process is monitored clinically and by the gradual normalization of the temperature difference between the two feet, and it commonly takes several months.
The stakes of getting this right early are substantial. In a 2024 cohort of 43 patients with acute stage 0/1 Charcot foot who were promptly offloaded with a total contact cast or removable knee-high device, 93% achieved complete remission at one year, with a mean time to remission of roughly 5.6 months and a major amputation rate of only 2.3% (Bittante et al., Journal of Clinical Medicine, 2024). These figures underscore a recurring theme in the literature: outcomes depend heavily on how quickly the diagnosis is made and immobilization is started.
Medical Therapy, Surgery, and the Role of a Team
Pharmacological treatments have been investigated as adjuncts to offloading. Agents aimed at slowing bone resorption, such as bisphosphonates and calcitonin, have been studied, but the evidence supporting them remains limited, and they are not considered a substitute for immobilization (Kavitha et al., 2021; Schweitzer and Rockhill, Clinics in Podiatric Medicine and Surgery, 2022). Surgery is generally reserved for feet with severe or unstable deformity, recurrent ulceration over bony prominences, or concurrent infection that conservative care cannot control. Techniques for reconstructing the collapsed hindfoot and ankle, including so-called “superconstruct” fixation, continue to evolve, and increasingly early and aggressive surgical correction in selected patients has been associated with improved quality of life and reduced amputation rates (Cellier, 2025).
Across all of these sources, one principle is constant: Charcot foot is best managed through a coordinated, multidisciplinary approach that combines glycemic and metabolic control, vigilant foot surveillance, offloading expertise, imaging, and surgical judgment when needed.
Key Takeaways
Charcot neuroarthropathy is a limb-threatening complication of diabetic neuropathy that often presents with a warm, swollen, relatively painless foot and can be mistaken for infection or injury. A high index of suspicion, prompt imaging (with MRI valuable for early-stage disease and for distinguishing Charcot from osteomyelitis), and immediate offloading with a total contact cast form the foundation of care. Evidence indicates that early recognition and immobilization are associated with high rates of remission and limb salvage, while delayed diagnosis remains the principal driver of deformity, ulceration, and amputation.
References
Wukich DK, Schaper NC, Gooday C, et al. Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023). Diabetes/Metabolism Research and Reviews. 2023;40(3):e3646. doi:10.1002/dmrr.3646
Bittante C, Cerasari V, Bellizzi E, et al. Early Treatment of Acute Stage 0/1 Diabetic Charcot Foot Can Avoid Major Amputations at One Year. Journal of Clinical Medicine. 2024;13(6):1633. doi:10.3390/jcm13061633
Cellier N. Management of hindfoot and ankle in Charcot arthropathy. EFORT Open Reviews. 2025;10(6):327-335. doi:10.1530/EOR-2025-0057
Bansod H, Wanjari A, Dumbhare O. A Review on Relationship Between Charcot Neuroarthropathy and Diabetic Patients. Cureus. 2023;15(12):e50988. doi:10.7759/cureus.50988
Kavitha KV, Patil VS, Sanjeevi CB, Unnikrishnan AG. New Concepts in the Management of Charcot Neuroarthropathy in Diabetes. Advances in Experimental Medicine and Biology. 2021;1307:391-415. doi:10.1007/5584_2020_498
Pitocco D, Scavone G, Di Leo M, et al. Charcot Neuroarthropathy: From the Laboratory to the Bedside. Current Diabetes Reviews. 2019;16(1):62-72. doi:10.2174/1573399815666190502121945
Schweitzer M, Rockhill S. Conservative Management of Charcot Neuroarthropathy. Clinics in Podiatric Medicine and Surgery. 2022;39(4):585-594. doi:10.1016/j.cpm.2022.05.005
Comments
